Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Down 97%, Is It Finally Time to Buy Invitae Stock?: https://g.foolcdn.com/editorial/images/740909/doctors-looking-at-tablet.jpg
Down 97%, Is It Finally Time to Buy Invitae Stock?

If you've only recently learned about Invitae (NYSE: NVTA), you can consider yourself lucky. A few years ago, the diagnostics business wowed Wall Street with plans to bring genetic testing to the

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Viatris Stock: Bull vs. Bear: https://g.foolcdn.com/editorial/images/740374/gettyimages-scientists-in-lab02.jpg
Viatris Stock: Bull vs. Bear

Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: SARTORIUS AG: Sartorius maintains high profitability despite the expected temporary declines in the first half of 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: SARTORIUS AG: Sartorius maintains high profitability despite the expected temporary declines in the first half of 2023
EQS-News: SARTORIUS AG: Sartorius maintains high profitability despite the expected temporary declines in the first half of 2023
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock: https://g.foolcdn.com/editorial/images/739959/a-person-sitting-with-their-child-looking-at-a-laptop.jpg
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock

A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Better Pharma Buy: Viatris vs. Pfizer: https://g.foolcdn.com/editorial/images/740301/gettyimages-women-investors.jpg
Better Pharma Buy: Viatris vs. Pfizer

Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their

Why Amarin Stock Is Sinking Today: https://g.foolcdn.com/editorial/images/740399/downsizing.jpg
Why Amarin Stock Is Sinking Today

Shares of Amarin (NASDAQ: AMRN) were sinking 22.7% as of 10:56 a.m. ET on Wednesday. The steep decline came after the drugmaker announced an organizational restructuring after the market close on

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Why Shares of Masimo Are Dropping Tuesday: https://g.foolcdn.com/editorial/images/740260/nurse-tending-patient-in-intensive-care-1.jpg
Why Shares of Masimo Are Dropping Tuesday

Shares of Masimo (NASDAQ: MASI) were down by 18.5% as of 1:30 p.m. on Tuesday. The patient monitoring company announced preliminary numbers for the second quarter after the markets closed on Monday

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
EQS-News: SARTORIUS AG: Sartorius completes acquisition of Polyplus: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: SARTORIUS AG: Sartorius completes acquisition of Polyplus
EQS-News: SARTORIUS AG: Sartorius completes acquisition of Polyplus
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Better High-Yield Dividend Stock: Altria or Viatris?: https://g.foolcdn.com/editorial/images/739969/dividends.jpg
Better High-Yield Dividend Stock: Altria or Viatris?

If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of

3 Reasons to Buy Viatris Stock, and 1 Reason to Sell: https://g.foolcdn.com/editorial/images/739304/team-of-medical-experts-talking-on-a-meeting-at-doctors-office.jpg
3 Reasons to Buy Viatris Stock, and 1 Reason to Sell

Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Why Shares of Silk Road Medical Are Dropping Wednesday: https://g.foolcdn.com/editorial/images/739495/moonlake.jpg
Why Shares of Silk Road Medical Are Dropping Wednesday

Shares of Silk Road Medical (NASDAQ: SILK) were down more than 33% as of 12:30 p.m. on Wednesday after the Centers for Medicare & Medicaid Services (CMS) announced a proposed change that could

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc